1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > Bone Disorders - Pipeline Review, H2 2013

Bone Disorders - Pipeline Review, H2 2013

  • July 2013
  • -
  • Global Markets Direct
  • -
  • 73 pages

Bone Disorders - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Bone Disorders - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Bone Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bone Disorders. Bone Disorders - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Bone Disorders.
- A review of the Bone Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Bone Disorders pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Bone Disorders.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Bone Disorders pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Bone Disorders - Pipeline Review, H2 2013
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Bone Disorders Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Bone Disorders 9
Bone Disorders Therapeutics under Development by Companies 11
Bone Disorders Therapeutics under Investigation by Universities/Institutes 13
Early Clinical Stage Products 15
Comparative Analysis 15
Discovery and Pre-Clinical Stage Products 16
Comparative Analysis 16
Bone Disorders Therapeutics - Products under Development by Companies 17
Bone Disorders Therapeutics - Products under Investigation by Universities/Institutes 18
Companies Involved in Bone Disorders Therapeutics Development 19
Sanofi-Aventis 19
Ablynx 20
BioMarin Pharmaceutical Inc. 21
Bayer AG 22
Enzo Biochem, Inc. 23
Medivir AB 24
Osteologix, Inc. 25
Alethia Biotherapeutics Inc. 26
Siena Biotech S.p.A. 27
Pharis Biotec GmbH 28
Prosensa Therapeutics B.V. 29
Bone Disorders - Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
ALX-0141 - Drug Profile 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
MIV-710 - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
MIV-711 - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
Enzo-D58 - Drug Profile 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
WX-04554 - Drug Profile 39
Product Description 39
Mechanism of Action 39
RandD Progress 39
BMN-111 - Drug Profile 40
Product Description 40
Mechanism of Action 40
RandD Progress 40
R-111 - Drug Profile 41
Product Description 41
Mechanism of Action 41
RandD Progress 41
Tsp50 Inhibitors - Drug Profile 42
Product Description 42
Mechanism of Action 42
RandD Progress 42
JP4-039 - Drug Profile 43
Product Description 43
Mechanism of Action 43
RandD Progress 43
Monoclonal Antibody For Bone Diseases - Drug Profile 45
Product Description 45
Mechanism of Action 45
RandD Progress 45
Drug For Bone Diseases and Osteoarthritis - Drug Profile 46
Product Description 46
Mechanism of Action 46
RandD Progress 46
Drug For Autoimmune Bone Diseases - Drug Profile 47
Product Description 47
Mechanism of Action 47
RandD Progress 47
APX-008 - Drug Profile 48
Product Description 48
Mechanism of Action 48
RandD Progress 48
Recombinant BMP-2 Biosimilar - Drug Profile 49
Product Description 49
Mechanism of Action 49
RandD Progress 49
P-881 - Drug Profile 50
Product Description 50
Mechanism of Action 50
RandD Progress 50
VS-110 - Drug Profile 51
Product Description 51
Mechanism of Action 51
RandD Progress 51
poncirin - Drug Profile 52
Product Description 52
Mechanism of Action 52
RandD Progress 52
ZK-191784 - Drug Profile 53
Product Description 53
Mechanism of Action 53
RandD Progress 53
ST-03 - Drug Profile 55
Product Description 55
Mechanism of Action 55
RandD Progress 55
Glucocorticoid-Induced Leucine Zipper - Drug Profile 56
Product Description 56
Mechanism of Action 56
RandD Progress 56
Matrix Metalloprotease And Pro-Inflammatory Cytokine Inhibitors - Drug Profile 57
Product Description 57
Mechanism of Action 57
RandD Progress 57
Allogeneic Stem Cells - Drug Profile 58
Product Description 58
Mechanism of Action 58
RandD Progress 58
Matrix Embedded Stem Cells - Drug Profile 59
Product Description 59
Mechanism of Action 59
RandD Progress 59
maspin - Drug Profile 60
Product Description 60
Mechanism of Action 60
RandD Progress 60
Promethazine Enantiomers - Drug Profile 61
Product Description 61
Mechanism of Action 61
RandD Progress 61
largazole - Drug Profile 62
Product Description 62
Mechanism of Action 62
RandD Progress 62
Drug For Bone Disorders - Drug Profile 64
Product Description 64
Mechanism of Action 64
RandD Progress 64
RNA-Modulation Program For Bone Diseases - Drug Profile 65
Product Description 65
Mechanism of Action 65
RandD Progress 65
Biphosphonate Series - Drug Profile 66
Product Description 66
Mechanism of Action 66
RandD Progress 66
Bone Disorders Therapeutics - Drug Profile Updates 67
Bone Disorders Therapeutics - Dormant Products 70
Bone Disorders - Product Development Milestones 71
Featured News and Press Releases 71
Mar 25, 2013: Bone Therapeutics Obtains European Manufacturing Authorization For Allogeneic Bone Cell Therapy Products 71
Appendix 72
Methodology 72
Coverage 72
Secondary Research 72
Primary Research 72
Expert Panel Validation 72
Contact Us 73
Disclaimer 73

List of Tables

Number of Products Under Development for Bone Disorders, H2 2013 9
Products under Development for Bone Disorders - Comparative Analysis, H2 2013 10
Number of Products under Development by Companies, H2 2013 12
Number of Products under Investigation by Universities/Institutes, H2 2013 14
Comparative Analysis by Early Clinical Stage Development, H2 2013 15
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 16
Products under Development by Companies, H2 2013 17
Products under Investigation by Universities/Institutes, H2 2013 18
Sanofi-Aventis, H2 2013 19
Ablynx, H2 2013 20
BioMarin Pharmaceutical Inc., H2 2013 21
Bayer AG, H2 2013 22
Enzo Biochem, Inc., H2 2013 23
Medivir AB, H2 2013 24
Osteologix, Inc., H2 2013 25
Alethia Biotherapeutics Inc., H2 2013 26
Siena Biotech S.p.A., H2 2013 27
Pharis Biotec GmbH, H2 2013 28
Prosensa Therapeutics B.V., H2 2013 29
Assessment by Monotherapy Products, H2 2013 30
Assessment by Stage and Route of Administration, H2 2013 32
Assessment by Stage and Molecule Type, H2 2013 34
Bone Disorders Therapeutics - Drug Profile Updates 67
Bone Disorders Therapeutics - Dormant Products 70

List of Figures

Number of Products under Development for Bone Disorders, H2 2013 9
Products under Development for Bone Disorders - Comparative Analysis, H2 2013 10
Products under Development by Companies, H2 2013 11
Products under Investigation by Universities/Institutes, H2 2013 13
Early Clinical Stage Products, H2 2013 15
Discovery and Pre-Clinical Stage Products, H2 2013 16
Assessment by Monotherapy Products, H2 2013 30
Assessment by Route of Administration, H2 2013 31
Assessment by Stage and Route of Administration, H2 2013 32
Assessment by Molecule Type, H2 2013 33
Assessment by Stage and Molecule Type, H2 2013 34

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - Pipeline Review, H2 2016

NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

NADPH Oxidase 4 (Kidney Oxidase 1 or KOX1 or Kidney Superoxide Producing NADPH Oxidase or Renal NAD(P)H Oxidase or NOX4 or EC 1.6.3.) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘NADPH ...

B1 Bradykinin Receptor (BK1 Receptor or BDKRB1) - Pipeline Review, H2 2016

B1 Bradykinin Receptor (BK1 Receptor or BDKRB1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

B1 Bradykinin Receptor (BK1 Receptor or BDKRB1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘B1 Bradykinin Receptor (BK1 Receptor or BDKRB1) - Pipeline Review, H2 2016’, provides ...

Lupus Nephritis - Pipeline Review, H2 2016

Lupus Nephritis - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • September 2016
  • by Global Markets Direct

Lupus Nephritis - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Lupus Nephritis - Pipeline Review, H2 2016’, provides an overview of the Lupus Nephritis pipeline landscape. The report ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.